348 related articles for article (PubMed ID: 33911289)
1. Epidemiology of Post-Kala-azar Dermal Leishmaniasis.
Ghosh P; Roy P; Chaudhuri SJ; Das NK
Indian J Dermatol; 2021; 66(1):12-23. PubMed ID: 33911289
[TBL] [Abstract][Full Text] [Related]
2. Improved kala-azar case management through implementation of health facility-based sentinel sites surveillance system in Bihar, India.
Das VNR; Siddiqui NA; Bhunia GS; Pandey K; Sinha SK; Ansari MZ; Topno RK; Lal CS; Ranjan A; Singh VP; Das P
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009598. PubMed ID: 34428232
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance identified a neglected burden of macular cases of Post Kala-azar Dermal Leishmaniasis in West Bengal.
Sengupta R; Chaudhuri SJ; Moulik S; Ghosh MK; Saha B; Das NK; Chatterjee M
PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007249. PubMed ID: 30856178
[TBL] [Abstract][Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
5. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
[TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
7. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
8. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas?
Addy M; Nandy A
Bull World Health Organ; 1992; 70(3):341-6. PubMed ID: 1638662
[TBL] [Abstract][Full Text] [Related]
9. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
[TBL] [Abstract][Full Text] [Related]
10. An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.
Routaray CB; Kumar A; Sundar S; Sathe G; Pawar H; Pai K
Acta Parasitol; 2022 Jun; 67(2):687-696. PubMed ID: 35020128
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of visceral leishmaniasis in India.
Bora D
Natl Med J India; 1999; 12(2):62-8. PubMed ID: 10416321
[TBL] [Abstract][Full Text] [Related]
12. PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
Ganguly S; Saha P; Chatterjee M; Roy S; Ghosh TK; Guha SK; Kundu PK; Bera DK; Basu N; Maji AK
PLoS Negl Trop Dis; 2015; 9(10):e0004138. PubMed ID: 26485704
[TBL] [Abstract][Full Text] [Related]
13. Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.
Mondal D; Bern C; Ghosh D; Rashid M; Molina R; Chowdhury R; Nath R; Ghosh P; Chapman LAC; Alim A; Bilbe G; Alvar J
Clin Infect Dis; 2019 Jul; 69(2):251-258. PubMed ID: 30357373
[TBL] [Abstract][Full Text] [Related]
14. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.
Zijlstra EE; el-Hassan AM; Ismael A
Am J Trop Med Hyg; 1995 Apr; 52(4):299-305. PubMed ID: 7741164
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
Singh S ; Kumar J; Singh R; Dwivedi SN
Int J Infect Dis; 2000; 4(4):203-8. PubMed ID: 11231183
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.
Islam S; Kenah E; Bhuiyan MA; Rahman KM; Goodhew B; Ghalib CM; Zahid MM; Ozaki M; Rahman MW; Haque R; Luby SP; Maguire JH; Martin D; Bern C
Am J Trop Med Hyg; 2013 Aug; 89(2):345-53. PubMed ID: 23817330
[TBL] [Abstract][Full Text] [Related]
17. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of molecular assays to detect Leishmania donovani in Phlebotomus argentipes fed on post-kala-azar dermal leishmaniasis patients.
Khan MAA; Faisal K; Chowdhury R; Nath R; Ghosh P; Ghosh D; Hossain F; Abd El Wahed A; Mondal D
Parasit Vectors; 2021 Sep; 14(1):465. PubMed ID: 34503557
[TBL] [Abstract][Full Text] [Related]
19. Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased
Cloots K; Marino P; Burza S; Gill N; Boelaert M; Hasker E
Front Cell Infect Microbiol; 2021; 11():604117. PubMed ID: 33777831
[TBL] [Abstract][Full Text] [Related]
20. Post Kala-Azar Dermal Leishmaniasis: Clinical Features and Differential Diagnosis.
Kumar P; Chatterjee M; Das NK
Indian J Dermatol; 2021; 66(1):24-33. PubMed ID: 33911290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]